公开(公告)号：US20230149540A1

公开(公告)日：2023-05-18

申请号：US17916942

申请日：2021-04-06

申请人： The Board of Trustees of the Leland Stanford Junior University

发明人： Thomas L. Cherpes ,  Rodolfo D. Vicetti Miguel

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/395 ,  A61K38/17 ,  C07K16/28 ,  A61P35/00

CPC分类号： A61K39/39 ,  A61K39/00119 ,  A61K39/3955 ,  A61K38/1774 ,  C07K16/2803 ,  A61P35/00 ,  A61K2039/55555 ,  A61K2039/55516

摘要： Compositions and methods are provided relating to vaccine formulations comprising (i) an agent that specifically binds to CD244; (ii) an effective dose of an antigen; and (iii) an adjuvant, which adjuvant can be, without limitation, an activator of innate-like T cells.

公开(公告)号：US20240156929A1

公开(公告)日：2024-05-16

申请号：US18465547

申请日：2023-09-12

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence J.N. COOPER ,  Hiroki TORIKAI ,  Ling ZHANG ,  Helen HULS ,  Feng WANG-JOHANNING ,  Lenka HURTON ,  Simon OLIVARES ,  Janani KRISHNAMURTHY

IPC分类号： A61K39/00 ,  A61K35/17 ,  A61P37/00 ,  C07K14/54 ,  C07K14/705 ,  C07K14/725 ,  C07K16/30

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/00111 ,  A61K39/001112 ,  A61K39/001113 ,  A61K39/001119 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/001151 ,  A61K39/001164 ,  A61K39/001168 ,  A61K39/00117 ,  A61K39/001171 ,  A61K39/001174 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/00119 ,  A61K39/001194 ,  A61P37/00 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  Y02A50/30

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US11883398B2

公开(公告)日：2024-01-30

申请号：US17551379

申请日：2021-12-15

申请人： INSTITUT PASTEUR ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

发明人： Rosa Barreira Da Silva ,  Matthew Albert

IPC分类号： A61K31/4985 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K31/4545 ,  A61K31/40 ,  A61K45/06 ,  A61K39/00 ,  A61P35/00 ,  A61K31/403 ,  A61K31/69 ,  A61K31/4375 ,  A61K47/68

CPC分类号： A61K31/4985 ,  A61K31/40 ,  A61K31/4545 ,  A61K31/513 ,  A61K31/522 ,  A61K35/17 ,  A61K39/001129 ,  A61K45/06 ,  A61P35/00 ,  A61K31/403 ,  A61K31/4375 ,  A61K31/69 ,  A61K39/0011 ,  A61K39/00117 ,  A61K39/00119 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001112 ,  A61K39/001124 ,  A61K39/001126 ,  A61K39/001135 ,  A61K39/001151 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001171 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001191 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K47/6803 ,  A61K2039/55561 ,  A61K2300/00 ,  A61K31/4985 ,  A61K2300/00 ,  A61K31/40 ,  A61K2300/00 ,  A61K31/403 ,  A61K2300/00 ,  A61K31/522 ,  A61K2300/00 ,  A61K31/513 ,  A61K2300/00 ,  A61K31/69 ,  A61K2300/00 ,  A61K31/4375 ,  A61K2300/00 ,  A61K31/4545 ,  A61K2300/00 ,  A61K35/17 ,  A61K2300/00 ,  A61K39/0011 ,  A61K2300/00

摘要： The success of anti-tumor immune responses requires effector T cells to infiltrate solid tumors, a process guided by chemokines. Herein, we demonstrate that in vivo post-translational processing of chemokines by dipeptidylpeptidase 4 (DPP4, also known as CD26) limits lymphocyte migration to sites of inflammation and tumors. Inhibition of DPP4 enzymatic activity enhanced tumor rejection by preserving biologically active CXCL10, and increasing trafficking into the tumor by lymphocytes expressing the counter-receptor CXCR3. Furthermore, DPP4 inhibition improved adjuvant-based immunotherapy, adoptive T cell transfer and checkpoint blockade. These findings provide the first direct in vivo evidence for controlling lymphocyte trafficking through CXCL10 cleavage and support the use of DPP4 inhibitors for stabilizing the biologically active form of chemokines as a strategy to enhance tumor immunotherapy.

公开(公告)号：US11786582B2

公开(公告)日：2023-10-17

申请号：US17223597

申请日：2021-04-06

申请人： BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

发明人： Laurence J N Cooper ,  Hiroki Torikai ,  Ling Zhang ,  Helen Huls ,  Feng Wang-Johanning ,  Lenka Hurton ,  Simon Olivares ,  Janani Krishnamurthy

IPC分类号： C07K14/54 ,  A61K39/00 ,  C07K14/725 ,  A61P37/00 ,  A61K35/17 ,  C07K14/705 ,  C07K16/30

CPC分类号： A61K39/0011 ,  A61K35/17 ,  A61K39/00117 ,  A61K39/00119 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001109 ,  A61K39/001112 ,  A61K39/001113 ,  A61K39/001119 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/001151 ,  A61K39/001164 ,  A61K39/001168 ,  A61K39/001171 ,  A61K39/001174 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/001194 ,  A61P37/00 ,  C07K14/5443 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/30 ,  A61K2039/505 ,  A61K2039/5158 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  Y02A50/30

摘要： The present invention concerns methods and compositions for immunotherapy employing a modified T cell comprising a chimeric antigen receptor (CAR). In particular aspects, CAR-expressing T-cells are producing using electroporation in conjunction with a transposon-based integration system to produce a population of CAR-expressing cells that require minimal ex vivo expansion or that can be directly administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20230302109A1

公开(公告)日：2023-09-28

申请号：US18046670

申请日：2022-10-14

申请人： The Francis Crick Institute Limited ,  Enara Bio Limited

发明人： George KASSIOTIS ,  George YOUNG ,  Jan ATTIG ,  Ambrosius SNIJDERS ,  David PERKINS ,  Fabio MARINO ,  Ray JUPP ,  Magdalena VON ESSEN ,  Peter MASON ,  Nicola TERNETTE

IPC分类号： A61K39/00 ,  C07K14/47 ,  A61P35/00

CPC分类号： A61K39/00119 ,  C07K14/4748 ,  A61P35/00 ,  A61K2039/876 ,  A61K2039/5158 ,  A61K2039/5154

摘要： There are disclosed inter alia antigen pools which are useful in the treatment of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma.

公开(公告)号：US20240269254A1

公开(公告)日：2024-08-15

申请号：US17282774

申请日：2019-10-04

申请人： Bavarian Nordic A/S

发明人： Henning Lauterbach ,  Jose Medina Echeverz ,  Maria Hinterberger

IPC分类号： A61K39/00 ,  A61P35/00

CPC分类号： A61K39/00119 ,  A61K39/001106 ,  A61P35/00 ,  A61K2039/5254 ,  A61K2039/5256 ,  A61K2039/545 ,  A61K2039/55516 ,  C12N2710/24134 ,  C12N2710/24171

摘要： The invention relates to a pharmaceutical combination and related methods for reducing tumor volume and/or increasing the survival of a cancer patient. The combination comprises an intravenous administration of a recombinant MVA encoding CD40L and an administration of an antagonist or agonist of an immune checkpoint molecule.

公开(公告)号：US11965177B2

公开(公告)日：2024-04-23

申请号：US17160952

申请日：2021-01-28

申请人： VERSITI BLOOD RESEARCH INSTITUTE FOUNDATION, INC.

发明人： Weiguo Cui

IPC分类号： C12N5/0783 ,  A61K9/00 ,  A61K35/17 ,  A61K39/00 ,  A61P35/00

CPC分类号： C12N5/0638 ,  A61K9/0019 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/00119 ,  A61K39/001192 ,  A61P35/00 ,  C12N5/0636 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/522 ,  A61K2039/523 ,  A61K2039/55594 ,  A61K2039/572 ,  A61K2039/585 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/50 ,  C12N2510/00 ,  Y02A50/30

摘要： The present invention relates to autologous dual-specific lymphocytes, methods of making and uses for the treatment of tumors. In particular, the invention relates to methods producing autologous dual-specific lymphocytes comprising an endogenous receptor for at least one tumor associated antigen and an exogenous receptor for a strong antigen

公开(公告)号：US20240082391A1

公开(公告)日：2024-03-14

申请号：US18260133

申请日：2022-01-05

申请人： NATIONAL RESEARCH COUNCIL OF CANADA

发明人： Yimei JIA ,  Michael MCCLUSKIE ,  Bassel AKACHE ,  Lakshmi KRISHNAN

IPC分类号： A61K39/39 ,  A61K39/00 ,  A61K39/215 ,  A61P35/00 ,  A61P37/04

CPC分类号： A61K39/39 ,  A61K39/00119 ,  A61K39/215 ,  A61P35/00 ,  A61P37/04 ,  A61K2039/55511 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/55577 ,  A61K2039/572 ,  A61K2039/575

摘要： Provided is an adjuvant composition comprising a glycoarchaeol and at least one immunostimulantselected from a Toll-like receptor (TLR) agonist and a saponin. The glycoarchaeol and/orimmunostimulant may be present as a pharmaceutically acceptable salt. The adjuvant compositionmay be comprised together with an antigen in an immunogenic composition, such as a vaccine composition, which may be for use to induce an immune response in a subject. Further provided isuse of the immunogenic composition to induce an immune response in a subject, particularly animmune response that comprises both a cell-mediated response and a humoral response.

公开(公告)号：US20230390371A1

公开(公告)日：2023-12-07

申请号：US18032183

申请日：2021-10-18

申请人： STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS

发明人： Reuven AGAMI ,  Abhijeet PATASKAR ,  Julien CHAMPAGNE ,  Yardena SAMUELS ,  Osnat BARTOK

IPC分类号： A61K39/00 ,  C12P21/02 ,  C07K14/435

CPC分类号： A61K39/00119 ,  C12P21/02 ,  C07K14/435 ,  A61K2039/70 ,  A61K2039/53 ,  A61K2039/876 ,  A61K2039/55522

摘要： The invention relates to methods of producing at least one out-of-frame peptide of 5-40 amino acid residues by a cell, and to methods of identifying said at least one out-of-frame peptide. The invention further relates to the identified out-of-frame peptides, and epitopes and polyepitopes encompassing at least one of said out-of-frame peptides, and to a nucleic acid molecule encoding at least one of said out-of-frame peptides. The invention further relates to methods of inducing an immune response against at least one out-of-frame peptide, method of treating an individual suffering from a tumor, comprising providing said individual with at least one out-of-frame peptide, and to a pharmaceutical composition, comprising at least one out-of-frame peptide. The invention additionally relates to a kit for detecting expression of at least one out-of-frame peptide, and to methods of typing an individual for presence or absence of a cell that expresses at least one out-of-frame peptide.

公开(公告)号：US20230310608A1

公开(公告)日：2023-10-05

申请号：US18003279

申请日：2021-07-01

申请人： TCER ONCOLOGY AB

发明人： Hans GRÖNLUND ,  Rolf KIESSLING ,  Stina WICKSTRÖM

IPC分类号： A61K39/00 ,  A61P35/00 ,  C12N5/0784 ,  C12N5/0783

CPC分类号： A61K39/46449 ,  A61K39/4611 ,  A61K39/00119 ,  A61P35/00 ,  C12N5/0639 ,  C12N5/0638 ,  A61K2039/5154 ,  A61K2039/5158 ,  C12N2502/1121 ,  C12N2502/1114

摘要： The present invention provides an in vitro method for the manufacture of a dendritic cell (DC) cancer vaccine, said method comprising the steps of: (i) providing a plurality of phagocytosable particles, wherein each phagocytosable particle comprises a core and an antigenic construct tightly associated to the core, wherein the antigenic construct comprises at least one epitope peptide having an amino acid sequence corresponding to an amino acid sequence of a part of a protein or peptide known or suspected to be expressed by a cancer cell in a subject; (ii) providing a sample of DCs; and (iii) contacting the sample of DCs with the plurality of phagocytosable particles in vitro and under conditions allowing for the phagocytosis of at least one phagocytosable particle by a DC. The present invention also provides a DC cancer vaccine produced by the method of the invention, and the use a DC cancer vaccine of the invention as a medicament and for the ex vivo expansion of anticancer T-cells.